Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mathias Schmidt

Showing results (81-90 of 104) with videos related to

Pageof 11
Sort By:
BMC Public Health|May 11, 2012
A pragmatic assessment of the relative efficiency of outreach chlamydia screening events conducted in non-clinical settingsFrancis J Bowden, Marian J Currie, Muareen Todkill, et al.
Cancers|December 31, 2020
Comprehensive Biology and Genetics Compendium of Wilms Tumor Cell Lines with Different <i>WT1</i> MutationsBrigitte Royer-Pokora, Maike Anna Busch, Sarah Tenbusch, et al.
Clinical Endocrinology|January 23, 2021
Radioiodine therapy reduces the frequency of circulating tumour cells in patients with differentiated thyroid cancerMathias Schmidt, Christina Antke, Katalin Mattes-György, et al.
Molecular and Cellular Endocrinology|May 26, 2016
The long N-terminus of the human monocarboxylate transporter 8 is a target of ubiquitin-dependent proteasomal degradation which regulates protein expression and oligomerization capacityDenise Zwanziger, Mathias Schmidt, Jana Fischer, et al.
Orphanet Journal of Rare Diseases|March 8, 2024
Analysis of caregiver perspectives on patients with mucopolysaccharidosis II treated with pabinafusp alfa: results of qualitative interviews in JapanKimitoshi Nakamura, Norio Sakai, Mohammad Arif Hossain, et al.
Journal of Medicinal Chemistry|September 15, 2006
[4-(imidazol-1-yl)thiazol-2-yl]phenylamines. A novel class of highly potent colchicine site binding tubulin inhibitors: synthesis and cytotoxic activity on selected human cancer cell linesSiavosh Mahboobi, Andreas Sellmer, Heymo Höcher, et al.
Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [Et Al.]|April 28, 2005
Overexpression of Polo-like kinase 1 is a common and early event in pancreatic cancerWilko Weichert, Mathias Schmidt, Juliane Jacob, et al.
Frontiers in Immunology|March 7, 2022
Reactivity of NK Cells Against Ovarian Cancer Cells Is Maintained in the Presence of Calcium Phosphate NanoparticlesAntonio Hrvat, Mathias Schmidt, Martin Obholzer, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|March 30, 2021
Iduronate-2-sulfatase fused with anti-hTfR antibody, pabinafusp alfa, for MPS-II: A phase 2 trial in BrazilRoberto Giugliani, Ana Maria Martins, Sairei So, et al.
Oncogene|May 23, 2003
HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cellsChristiane Knuefermann, Yang Lu, Bolin Liu, et al.
Pageof 11

Showing results (81-90 of 104) with videos related to

Sort By:
Pageof 11
BMC Public Health|May 11, 2012
A pragmatic assessment of the relative efficiency of outreach chlamydia screening events conducted in non-clinical settingsFrancis J Bowden, Marian J Currie, Muareen Todkill, et al.
Cancers|December 31, 2020
Comprehensive Biology and Genetics Compendium of Wilms Tumor Cell Lines with Different <i>WT1</i> MutationsBrigitte Royer-Pokora, Maike Anna Busch, Sarah Tenbusch, et al.
Clinical Endocrinology|January 23, 2021
Radioiodine therapy reduces the frequency of circulating tumour cells in patients with differentiated thyroid cancerMathias Schmidt, Christina Antke, Katalin Mattes-György, et al.
Molecular and Cellular Endocrinology|May 26, 2016
The long N-terminus of the human monocarboxylate transporter 8 is a target of ubiquitin-dependent proteasomal degradation which regulates protein expression and oligomerization capacityDenise Zwanziger, Mathias Schmidt, Jana Fischer, et al.
Orphanet Journal of Rare Diseases|March 8, 2024
Analysis of caregiver perspectives on patients with mucopolysaccharidosis II treated with pabinafusp alfa: results of qualitative interviews in JapanKimitoshi Nakamura, Norio Sakai, Mohammad Arif Hossain, et al.
Journal of Medicinal Chemistry|September 15, 2006
[4-(imidazol-1-yl)thiazol-2-yl]phenylamines. A novel class of highly potent colchicine site binding tubulin inhibitors: synthesis and cytotoxic activity on selected human cancer cell linesSiavosh Mahboobi, Andreas Sellmer, Heymo Höcher, et al.
Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [Et Al.]|April 28, 2005
Overexpression of Polo-like kinase 1 is a common and early event in pancreatic cancerWilko Weichert, Mathias Schmidt, Juliane Jacob, et al.
Frontiers in Immunology|March 7, 2022
Reactivity of NK Cells Against Ovarian Cancer Cells Is Maintained in the Presence of Calcium Phosphate NanoparticlesAntonio Hrvat, Mathias Schmidt, Martin Obholzer, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|March 30, 2021
Iduronate-2-sulfatase fused with anti-hTfR antibody, pabinafusp alfa, for MPS-II: A phase 2 trial in BrazilRoberto Giugliani, Ana Maria Martins, Sairei So, et al.
Oncogene|May 23, 2003
HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cellsChristiane Knuefermann, Yang Lu, Bolin Liu, et al.
Pageof 11